M&A - KINETA, INC./DE

Form Type: 425

Filing Date: 2025-04-08

Corporate Action: Merger

Type: New

Accession Number: 000119312525075222

Filing Summary: On April 7, 2025, TuHURA Biosciences, Inc. announced the acceptance of abstracts for poster presentations at the upcoming 2025 AACR Annual Meeting. The abstracts include one focusing on Kineta, Inc.'s KVA12123 antibody and another on the IFx-Hu2.0 therapy for advanced melanoma. A definitive agreement was announced on December 11, 2024, in which TuHURA will acquire Kineta in a merger transaction, expected to close in Q2 2025, pending various conditions. The merger will involve cash and shares of TuHURA common stock.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-03-07

Corporate Action: Merger

Type: New

Accession Number: 000095017025035463

Filing Summary: On March 7, 2025, Kineta, Inc. entered into a securities exchange agreement with an existing investor. Under this agreement, Kineta will issue 1,880,342 shares of common stock and a pre-funded warrant to purchase additional shares in exchange for certain outstanding warrants held by the investor. This transaction is part of a larger merger agreement with TuHURA Biosciences, which involves stockholder approval for the proposed transactions. The issuance of shares is exempt from SEC registration, but shares may not be sold without proper registration. Additionally, the document acknowledges the risk factors related to the merger, including potential changes to financial conditions, delays in merger completion, and other uncertainties.

Document Link: View Document

Form Type: 10-K

Filing Date: 2025-03-06

Corporate Action: Merger

Type: Update

Accession Number: 000095017025034880

Filing Summary: Kineta, Inc. underwent a merger with Yumanity Therapeutics, Inc. that was completed on December 16, 2022. This involved the merger of Kineta Operating, Inc. into Yumanity, resulting in Yumanity becoming Kineta, Inc. Following this, a reverse stock split was executed. The company is exploring strategic alternatives, including asset sales and potential liquidation or bankruptcy if the merger with TuHURA Biosciences, Inc. does not proceed. Furthermore, Kineta has reported that trading in its securities is highly speculative and advices caution to investors regarding potential risks. The overall focus remains on maximizing shareholder value through these strategic actions. Regulatory compliance, risk factors, and financial management are also key areas discussed in the filing.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-02-10

Corporate Action: Merger

Type: New

Accession Number: 000095017025016482

Filing Summary: Kineta, Inc. announced that on December 11, 2024, it entered into a Merger Agreement with TuHURA Biosciences, Inc., which involves multiple subsidiaries of TuHURA and arrangements made regarding asset disposals. Effective January 29, 2025, Kineta terminated its existing agreement with GigaGen, which granted rights for the CD27 drug program, resulting in a waiver of fees amounting to $180,000 and the transfer of associated intellectual property back to GigaGen. Additionally, on February 4, 2025, Kineta Chronic Pain, LLC agreed to sell certain assets related to the KCP506 program to Pacira Pharmaceuticals for $450,000 and entered into another asset purchase agreement with HCRX Investments Holdco to transfer specific intellectual property assets for a nominal fee of $1.00 while excluding several liabilities and rights. Kineta indicates ongoing communication regarding the merger and related transactions, urging stockholders from both Kineta and TuHURA to review important documentation, such as the forthcoming definitive joint proxy statement/prospectus.

Document Link: View Document